ANAPTYSBIO, INC
Close on Oct 19, 2026
- Market cap
- $2.28B
- P/E (TTM)
- –
- Dividend yield
- –
About Anaptysbio
Pharmaceutical Preparations, SIC 2834
AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the research, development, and commercialization of antibody product candidates. The company develops therapeutic antibodies targeting various diseases across its research, development, and collaborative program segments. Its pipeline and partnered assets include rosnilimab, imsidolimab, ANB032, ANB033, ANB101, and dostarlimab, an anti-PD-1 therapy marketed under the name Jemperli. The company partners with and licenses its therapeutic assets to global biopharmaceutical corporations, including GlaxoSmithKline, Vanda Pharmaceuticals, and Centessa Pharmaceuticals.
The company conducts clinical trials and research operations in the United States and internationally, including Australia, in coordination with regulatory bodies such as the U.S. Food and Drug Administration and foreign health authorities. AnaptysBio is incorporated in Delaware and maintains its principal executive offices and operational facilities in San Diego, California.
Summary of the business section of Anaptysbio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ANAPTYSBIO, INC
- Headquarters
- San Diego, CA
- Address
- 10770 Wateridge Circle, Suite 210 92121
- Phone
- (858) 362-6295
- Website
- anaptysbio.com
- Employees
- 104, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- ANAB
- Exchange
- Nasdaq
- IPO date
- Jan 26, 2017
- Shares outstanding
- 30M, Sep 16, 2026
- Public float
- $632.72M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 15-for-10, Apr 20, 2026
- SEC CIK
- 1370053
- CUSIP
- 032724106
- ISIN
- US0327241065
- LEI
- 529900HH4WQT03IG1A12
- EIN
- 20-3828755
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Faga | President, CEO, Director | 510,564 |
| Paul F. Lizzul | Chief Medical Officer | 42,088 |
| Christopher M. Murphy | Chief Financial Officer | – |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | 12,835 |
| Dennis Mulroy | CHIEF FINANCIAL OFFICER | 21,852 |
| John A. Orwin | Director | 17,995 |
| John P. Schmid | Director | 37,652 |
| Hollings Renton | Director | 10,995 |
| Owen Hughes | Director | – |
| Susannah Gray | Director | – |
| Magda Marquet | Director | 20,930 |
| J. Anthony Ware | Director | 9,630 |
| Rita Jain | Director | 11,864 |
| Dennis M. Fenton | Director | 4,965 |
| EcoR1 Capital, LLC | Director | 7,880,094 |
| Oleg Nodelman | Director | 7,520,424 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Daniel Faga | $6.13M | $41.74M | $2.19M | $156 | – |
| FY2024 Daniel Faga | $13.63M | $9.16M | $3.91M | $43 | – |
| FY2023 Daniel Faga | $7.46M | -$1.74M | $2.35M | $69 | – |
| FY2022 Daniel Faga | $24.44M | $28.51M | $3.83M | $89 | – |
| FY2022 Hamza Suria | $7.25M | $3.71M | $3.83M | $89 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of January 31, 2026, we had 104 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 20, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 1, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 26, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 17, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 20, 2007 | Name change | Name changed from ANAPTYS BIOSCIENCES INC to ANAPTYSBIO INC |